Rallybio

RLYB - Rallybio • Financials

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
-79
-
0%
L
106
L
-110
-
-71
-0
0
-71
0
0
-
-
12/2024
1
-60
-
L
L
62
L
-66
-
-57
0
5
-57
0
0
-
-
12/2025
1
-33
-
L
L
58
L
-55
-
-35
0
0
-35
0
0
-
-